{
  "data": [
    {
      "patent_number": "5202128",
      "expiration_date": "2010-04-13",
      "published_date": "2000-04-13",
      "application_numbers": [
        "NDA022321",
        "NDA020616"
      ],
      "claims": [
        {
          "claim_number": 1,
          "claim_text": "1. A pH-dependent sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing a therapeutically effective amount of at least one active ingredient having an aqueous solubility of at least 1 in 30 and a coating on said core element which comprises the following components:(a) at least 35% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;said percentages being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval.",
          "dependencies": null
        },
        {
          "claim_number": 2,
          "claim_text": "2. The sustained release pharmaceutical pellet composition of claim 1 wherein the coating contains:as component (a), ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof;as component (b), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid:acrylic acid ester copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate and mixtures thereof; andas component (c), polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol having a molecular weight of from 1700 to 20,000polyvinyl alcohol and monomers therefor and mixtures thereof.",
          "dependencies": "1"
        },
        {
          "claim_number": 3,
          "claim_text": "3. The sustained release pharmaceutical pellet composition of claim 35 wherein the active ingredient of high solubility is selected from the group consisting of antihistamines, antibiotics, antituberculosis agents, cholinergic agents, antimuscarinics, sympathomimetics, sympatholytic agents, autonomic drugs, iron preparations, haemostatics, cardiac drugs, antihypertensive agents, vasodilators, non-steroidal antiinflammatory agents, opiate agonists, anticonvulsants, tranquilizers, stimulants, barbiturates, sedatives, expectorants, antiemetics, gastrointestinal drugs, heavy metal antagonists, antithyroid agents, genitourinary smooth muscle relaxants and vitamins.",
          "dependencies": "35"
        },
        {
          "claim_number": 4,
          "claim_text": "4. The sustained release pharmaceutical pellet composition of claim 3 wherein the active ingredient is an opiate agonist selected from the group consisting of the salts of codeine, dextromoramide, hydrocodone, hydromorphine, pethidine, methadone, morphine and propoxyphene.",
          "dependencies": "3"
        },
        {
          "claim_number": 5,
          "claim_text": "5. The sustained release pharmaceutical pellet composition of claim 1 wherein the active ingredient has a first dissolution profile measured at a pH of from 1 to 4, and a second dissolution profile measured at a pH of about 7.5 and wherein said first and second dissolution profile are each at least equal to the minimum dissolution required to provide substantially the same bio-availability as with an immediate release oral dosage form.",
          "dependencies": "1"
        },
        {
          "claim_number": 6,
          "claim_text": "6. The sustained release pharmaceutical pellet composition of claim 5 wherein the composition, in use, minimizes fluctuations in the plasma concentration of the active ingredient in said patient.",
          "dependencies": "5"
        },
        {
          "claim_number": 7,
          "claim_text": "7. The sustained release pharmaceutical pellet composition of claim 2 wherein the coating comprises:35to 75% by weight of component (a);2-20% by weight of component (b); and15-50% by weight of component (c).",
          "dependencies": "2"
        },
        {
          "claim_number": 8,
          "claim_text": "8. The sustained release pharmaceutical pellet composition of claim 2 wherein the coating also includes up to 50% of plasticizer selected from diethyl phthalate, triethyl citrate, triethyl acetyl citrate, triethyl acetin, tributyl citrate, polyethylene glycol having a molecular weight of from 200 to less than 1700 or glycerol and up to 75% of a filler selected from silicon dioxide, titanium dioxide, talc, alumina, starch, kaolin, polacrilin potassium, powdered cellulose and microcrystalline cellulose and mixtures thereof, said percentages being based on the total weight of the coating.",
          "dependencies": "2"
        },
        {
          "claim_number": 9,
          "claim_text": "9. The sustained release pharmaceutical pellet composition of claim 8 wherein the coating contains: component (a) 35 to 70% component (b) 4 to 20% component (c) 15 to 35% plasticizer 4 to 30%.  ",
          "dependencies": "8"
        },
        {
          "claim_number": 10,
          "claim_text": "10. A pH-dependent sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing a therapeutically effective amount of an acid addition salt of morphine and a coating on said core element which comprises the following components:(a) at least 35% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;said percentages being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval.",
          "dependencies": null
        },
        {
          "claim_number": 11,
          "claim_text": "11. The sustained release pharmaceutical pellet composition of claim 10 wherein said acid addition salt of morphine is morphine sulphate.",
          "dependencies": "10"
        },
        {
          "claim_number": 12,
          "claim_text": "12. The sustained release pharmaceutical pellet composition of claim 10 wherein the rate of release in the intestine is 1.2 to 3 times greater than the rate of release in the stomach.",
          "dependencies": "10"
        },
        {
          "claim_number": 13,
          "claim_text": "13. The sustained release pharmaceutical pellet composition of claim 10 wherein the composition, in use, minimizes fluctuations in the morphine compound concentration in the plasma of said patient.",
          "dependencies": "10"
        },
        {
          "claim_number": 14,
          "claim_text": "14. The sustained release pharmaceutical pellet composition of claim 13 wherein, in use, the time during which the concentration of the morphine compound is greater than or equivalent to 75% of maximum morphine compound concentration in the plasma is at least 3 hours.",
          "dependencies": "13"
        },
        {
          "claim_number": 15,
          "claim_text": "15. The sustained release pharmaceutical pellet composition of claim 10 wherein the coating contains:as component (a), ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof;as component (b), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid ester copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate and mixtures thereof; andas component (c), polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol having a molecular weight of from 1700 to 20,000, polyvinyl alcohol and monomers therefor and mixtures thereof.",
          "dependencies": "10"
        },
        {
          "claim_number": 16,
          "claim_text": "16. The sustained release pharmaceutical pellet composition of claim 15 wherein the coating comprises:35 to 75% by weight of component (a);2-20% by weight of component (b); and15-40% by weight of component (c).",
          "dependencies": "15"
        },
        {
          "claim_number": 17,
          "claim_text": "17. The sustained release pharmaceutical pellet composition of claim 49 wherein the coating comprises: [high molecular weight] 15 to 40% polyethylene glycol having a molecular weight of from 1700 to 20,000 ethylcellulose 45 to 65% methacrylic acid:acrylic 4 to 20%. acid ethylester 1:1 copolymer  ",
          "dependencies": "49"
        },
        {
          "claim_number": 18,
          "claim_text": "18. A method for treating a pain associated with a condition in a patient which comprises administering to said patient at a predetermined dosage and interval a pH-dependent sustained release pharmaceutical pellet composition which comprises: a core element containing a therapeutically effective amount of an active compound having an aqueous solubility of at least 1 in 30 and a coating on said core element which comprises the following components:(a) at least 35% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;said percentage being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval.",
          "dependencies": null
        },
        {
          "claim_number": 19,
          "claim_text": "19. The method of claim 18 wherein the pain associated conditions relate to the treatment of acute and chronic pain.",
          "dependencies": "18"
        },
        {
          "claim_number": 20,
          "claim_text": "20. The method of claim 19 wherein the sustained release pharmaceutical pellet composition is provided in a unit dosage form and the predetermined interval is approximately 8 to 24 hours.",
          "dependencies": "19"
        },
        {
          "claim_number": 21,
          "claim_text": "21. The method of claim 18 wherein the active ingredient is an acid addition salt of morphine.",
          "dependencies": "18"
        },
        {
          "claim_number": 22,
          "claim_text": "22. The method of claim 21 wherein the acid addition salt is morphine sulphate.",
          "dependencies": "21"
        },
        {
          "claim_number": 23,
          "claim_text": "23. The method of claim 21 wherein the acid addition salt is morphine hydrochloride.",
          "dependencies": "21"
        },
        {
          "claim_number": 24,
          "claim_text": "24. A pH-dependent sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing a therapeutically effective amount of at least one active ingredient having an aqueous solubility of a least 1 in 30 and a coating on said core element which comprises the following components:(a) at least 35% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and is composed of ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof which contributes to the control of the release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;said percentages being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval.",
          "dependencies": null
        },
        {
          "claim_number": 25,
          "claim_text": "25. A pH-dependent sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing a therapeutically effective amount of an acid addition salt of morphine and a coating on said core element which comprises the following components:(a) at least 35% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and is composed of ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof which contributes to the control of the release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;said percentages being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval.",
          "dependencies": null
        },
        {
          "claim_number": 26,
          "claim_text": "26. A method for treating a pain associated with a condition in a patient which comprises administering to said patient at a predetermined dosage and interval a pH-dependent sustained release pharmaceutical pellet composition which comprises: a core element containing a therapeutically effective amount of an active compound having an aqueous solubility of at least 1 in 30 and a coating on said core element which comprises the following components:(a) at least 35% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and is composed of ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof which contributes to the control of the release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;said percentage being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being effective to allow the initiation of the release of the active ingredient in the stomach at a slow rate and to control the release in the intestines at a rate faster than that in the stomach such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval.",
          "dependencies": null
        }
      ]
    },
    {
      "patent_number": "5378474",
      "expiration_date": "2010-03-23",
      "published_date": "2000-03-23",
      "application_numbers": [
        "NDA022321",
        "NDA020616"
      ],
      "claims": [
        {
          "claim_number": 1,
          "claim_text": "1. A sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing a therapeutically effective amount of at least one active ingredient having an aqueous solubility of at least 1 in 30 and a coating on said core element which comprises the following components:(a) from 1 to 85% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach; said percentages being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval, so as to maintain an active ingredient blood level at steady state of at least 75% of maximum blood level for more than approximately 4 hours and so that the time at which the active ingredient reaches its maximum concentration is between about 4 and about 30 hours.",
          "dependencies": null
        },
        {
          "claim_number": 2,
          "claim_text": "2. The sustained release pharmaceutical pellet composition of claim 1 wherein the time at which the active ingredient reaches its maximum concentration is between about 4 and about 12 hours.",
          "dependencies": "1"
        },
        {
          "claim_number": 3,
          "claim_text": "3. The sustained release pharmaceutical pellet composition of claim 1 wherein the active ingredient of high solubility is selected from the group consisting of antihistamines, antibiotics, antituberculosis agents, cholinergic agents, antimuscarinics, sympathomimetics, sympatholytic agents, autonomic drugs, iron preparations, haemostatics, cardiac drugs, antihypertensive agents, vasodilators, non-steroidal antiinflammatory agents, opiate agonists, anticonvulsants, tranquilizers, stimulants, barbiturates, sedatives, expectorants, antiemetics, gastrointestinal drugs, heavy metal antagonists, antithyroid agents, genitourinary smooth muscle relaxants and vitamins.",
          "dependencies": "1"
        },
        {
          "claim_number": 4,
          "claim_text": "4. The sustained release pharmaceutical pellet composition of claim 3 wherein the active ingredient is an opiate agonist selected from the group consisting of the salts of codeine, dextromoramide, hydrocodone, hydromorphine, pethidine, methadone, morphine and propoxyphene.",
          "dependencies": "3"
        },
        {
          "claim_number": 5,
          "claim_text": "5. The sustained release pharmaceutical pellet composition of claim 1 wherein the active ingredient has a first dissolution profile measured at a pH of from 1 to 4, and a second dissolution profile measured at a pH of about 7.5 and wherein said first and second dissolution profile are each at least equal to the minimum dissolution required to provide substantially the same bio-availability as with an immediate release oral dosage form.",
          "dependencies": "1"
        },
        {
          "claim_number": 6,
          "claim_text": "6. The sustained release pharmaceutical pellet composition of claim 5 wherein the composition, in use, minimizes fluctuations in the plasma concentration of the active ingredient in said patient.",
          "dependencies": "5"
        },
        {
          "claim_number": 7,
          "claim_text": "7. The sustained release pharmaceutical pellet composition of claim 1 wherein the coating contains:as component (a), ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof;as component (b), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid:acrylic acid ester copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate and mixtures thereof; andas component (c), polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol having a molecular weight of from 1700 to 20,000, polyvinyl alcohol and monomers therefor and mixtures thereof.",
          "dependencies": "1"
        },
        {
          "claim_number": 8,
          "claim_text": "8. The sustained release pharmaceutical pellet composition of claim 7 wherein the coating comprises:35 to 75% by weight of component (a);2-20% by weight of component (b); and15-40% by weight of component (c).",
          "dependencies": "7"
        },
        {
          "claim_number": 9,
          "claim_text": "9. The sustained release pharmaceutical pellet composition of claim 7 wherein the coating also includes up to 50% of plasticizer selected from diethyl phthalate, triethyl citrate, triethyl acetyl citrate, triethyl acetin, tributyl citrate, polyethylene glycol having a molecular weight of from 200 to less than 1700 or glycerol and up to 75% of a filler selected from silicon dioxide, titanium dioxide, talc, alumina, starch, kaolin, polacrilin potassium, powdered cellulose and microcrystalline cellulose and mixtures thereof, said percentages being based on the total weight of the coating.",
          "dependencies": "7"
        },
        {
          "claim_number": 10,
          "claim_text": "10. The sustained release pharmaceutical pellet composition of claim 9 wherein the coating contains:component (a) 35 to 70%component (b) 4 to 20%component (c) 15 to 35%plasticizer 4 to 30%.",
          "dependencies": "9"
        },
        {
          "claim_number": 11,
          "claim_text": "11. A sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing as the active ingredient a therapeutically effective amount of an acid addition salt of morphine and a coating on said core element which comprises the following components:(a) from 1% to 85% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach;said percentages being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval, so as to maintain an active ingredient blood level at steady state of at least 75% of maximum blood level for more than approximately 4 hours and so that the time at which the active ingredient reaches its maximum concentration is between about 4 and about 30 hours.",
          "dependencies": null
        },
        {
          "claim_number": 12,
          "claim_text": "12. The sustained release pharmaceutical pellet composition of claim 11 wherein the time at which the active ingredient reaches its maximum concentration is between about 4 and about 12 hours.",
          "dependencies": "11"
        },
        {
          "claim_number": 13,
          "claim_text": "13. The sustained release pharmaceutical pellet composition of claim 11 wherein said acid addition salt of morphine is morphine sulphate.",
          "dependencies": "11"
        },
        {
          "claim_number": 14,
          "claim_text": "14. The sustained release pharmaceutical pellet composition of claim 11 wherein the composition, in use, minimizes fluctuations in the morphine compound concentration in the plasma of said patient.",
          "dependencies": "11"
        },
        {
          "claim_number": 15,
          "claim_text": "15. The sustained release pharmaceutical pellet composition of claim 11 wherein the coating contains:as component (a), ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof;as component (b), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid ester copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate and mixtures thereof; andas component (c), polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol having a molecular weight of from 1700 to 20,000, polyvinyl alcohol and monomers therefore and mixtures thereof.",
          "dependencies": "11"
        },
        {
          "claim_number": 16,
          "claim_text": "16. The sustained release pharmaceutical pellet composition of claim 15 wherein the coating comprises:35 to 75% by weight of component (a);2-20% by weight of component (b); and15-40% by weight of component (c).",
          "dependencies": "15"
        },
        {
          "claim_number": 17,
          "claim_text": "17. The sustained release pharmaceutical pellet composition of claim 15 wherein the coating comprises:polyethylene glycol having a molecular weight of from 1700 to 20,000 15 to 40%ethylcellulose 45 to 65%methacrylic acid: acrylicacid ethylester 1:1 copolymer 4 to 20%.",
          "dependencies": "15"
        },
        {
          "claim_number": 18,
          "claim_text": "18. A sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing a therapeutically effective amount of at least one active ingredient having an aqueous solubility of at least 1 in 30 and a coating on said core element which comprises the following components:(a) at least 35% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and is composed of ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof which contributes to the control of the release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach; said percentages being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval, so as to maintain an active ingredient blood level at steady state of at least 75% of maximum blood level for more than approximately 4 hours and so that the time at which the active ingredient reaches its maximum concentration is between about 4 and about 30 hours.",
          "dependencies": null
        },
        {
          "claim_number": 19,
          "claim_text": "19. The sustained release pharmaceutical pellet composition of claim 18 wherein the time at which the active ingredient reaches its maximum concentration is between about 4 and about 12 hours.",
          "dependencies": "18"
        },
        {
          "claim_number": 20,
          "claim_text": "20. A sustained release pharmaceutical pellet composition for administration to a patient at a predetermined dosage and interval which comprises: a core element containing as the active ingredient a therapeutically effective amount of an acid addition salt of morphine and a coating on said core element which comprises the following components:(a) at least 35% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and is composed of ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof which contributes to the control of the release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines;(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach; said percentages being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in said coating being such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of said active ingredient over the course of said predetermined interval, so as to maintain an active ingredient blood level at steady state of at least 75% of maximum blood level for more than approximately 4 hours and so that the time at which the active ingredient reaches its maximum concentration is between about 4 and about 30 hours.",
          "dependencies": null
        },
        {
          "claim_number": 21,
          "claim_text": "21. The sustained release pharmaceutical pellet composition of claim 20 wherein the time at which the active ingredient reaches its maximum concentration is between about 4 and about 12 hours.",
          "dependencies": "20"
        }
      ]
    },
    {
      "patent_number": "5807572",
      "expiration_date": "2015-09-15",
      "published_date": "2005-09-15",
      "application_numbers": [
        "NDA021671"
      ],
      "claims": [
        {
          "claim_number": 1,
          "claim_text": "A process for producing a multivesicular liposome having multiple non-concentric chambers with membranes distributed in a matrix, the process comprising the steps of: (a) forming a water-in-oil emulsion from two immiscible components, the two immiscible components being (1) a lipid component comprising at least one organic solvent, at least one amphipathic lipid, and a neutral lipid lacking a hydrophilic head group, and (2) a first aqueous component; said water-in-oil emulsion further comprising a hydrochloride selected from the group consisting of hydrochloric acid, arginine hydrochloride, histidine hydrochloride, lysine hydrochloride and pyridine hydrochloride, and combinations thereof, in a concentration in the range from about 10 mM to about 500 mM and at least one biologically active substance selected from the group consisting of an anesthetic, an antiasthmatic agent, a cardiac glycoside, an antihypertensive, a nucleic acid, an antibiotic, a vaccine, an antiarrhythmic, an antiangina, a hormone, an antidiabetic, at antineoplastic, an immunomodulator, an antifungal, a tranquilizer, a steroid, a sedative, an analgesic, a vasopressor, an antiviral, a herbicide, a pesticide, a protein, a peptide, a neurotransmitter, a radionuclide, and suitable combinations thereof, said hydrochloride and biologically active agent being independently incorporated into either the lipid component or the first aqueous component, or into both; (b) dispersing the water-in-oil emulsion containing the hydrohalide into a second aqueous component to form solvent spherules; and thereafter (c) removing the organic solvent from the solvent spherules to form the multivesicular liposomes suspended in the second aqueous component; wherein the hydrohalide concentration in the water-in-oil emulsion is chosen to modulate the in vivo release rate of the biologically active substance. ",
          "dependencies": null
        },
        {
          "claim_number": 2,
          "claim_text": "The process of claim 1 wherein, the hydrohalide is hydrochloric acid. ",
          "dependencies": "1"
        },
        {
          "claim_number": 3,
          "claim_text": "The process of claim 1 wherein, the hydrochloride is chosen from the group consisting of lysine hydrochloride, histidine hydrochloride, arginine hydrochloride, and combinations thereof. ",
          "dependencies": "1"
        },
        {
          "claim_number": 4,
          "claim_text": "The process of claim 1 wherein, the amphipathic lipid comprises at least one zwitterionic amphipathic lipid. ",
          "dependencies": "1"
        },
        {
          "claim_number": 5,
          "claim_text": "The process of claim 1 wherein, the amphipathic lipid comprises at least one cationic amphipathic lipid. ",
          "dependencies": "1"
        },
        {
          "claim_number": 6,
          "claim_text": "The process of claim 1 wherein, the amphipathic lipid comprises at least one anionic amphipathic lipid. ",
          "dependencies": "1"
        },
        {
          "claim_number": 7,
          "claim_text": "The process of claim 1 wherein, the amphipathic lipid comprises at least one zwitterionic and at least one cationic amphipathic lipid. ",
          "dependencies": "1"
        },
        {
          "claim_number": 8,
          "claim_text": "The process of claim 1 wherein, the amphipathic lipid comprises at least one zwitterionic and at least one anionic amphipathic lipid. ",
          "dependencies": "1"
        },
        {
          "claim_number": 9,
          "claim_text": "The process according to claim 4, 5, 6, 7, or 8 wherein, the amphipathic lipid is selected from the group consisting of phospholipids. ",
          "dependencies": "4,5,6,7,8"
        },
        {
          "claim_number": 10,
          "claim_text": "The process according to claim 9 wherein, the phospholipids are selected from the group consisting of phosphatidylcholine, cardiolipin, phosphatidylethanolamine, sphingomyelin, lysophosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and phosphatidic acid. ",
          "dependencies": "9"
        },
        {
          "claim_number": 11,
          "claim_text": "The process according to claim 1 or 2 wherein, the lipid component further comprises. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 12,
          "claim_text": "The process according to claim 1 or 2 wherein, the lipid component further comprises stearylamine, or diacyl dimethylammoniumpropane, or diacyl trimethylammoniumpropane. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 13,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is lipophilic and is incorporated into the lipid component. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 14,
          "claim_text": "The process according to claims 4, 5, 6, 7, or 8 wherein, the neutral lipid is a triglyceride. ",
          "dependencies": "4,5,6,7,8"
        },
        {
          "claim_number": 15,
          "claim_text": "The process according to claims 4, 5, 6, 7, or 8 wherein, the neutral lipid is a diglyceride. ",
          "dependencies": "4,5,6,7,8"
        },
        {
          "claim_number": 16,
          "claim_text": "The process according to claims 4, 5, 6, 7, or 8 wherein, the neutral lipid is a propylene glycol ester. ",
          "dependencies": "4,5,6,7,8"
        },
        {
          "claim_number": 17,
          "claim_text": "The process according to claim 14 wherein, the triglyceride is selected from the group consisting of triolein, tripalmitolein, trimyristolein, trilinolein, tributyrin, tricaproin, tricaprylin, tricaprin, trilaurin, and combinations thereof. ",
          "dependencies": "14"
        },
        {
          "claim_number": 18,
          "claim_text": "The process according to claim 15 wherein, the diglyceride is selected from the group consisting of diolein and dipalmitolein. ",
          "dependencies": "15"
        },
        {
          "claim_number": 19,
          "claim_text": "The process according to claim 16 wherein, the propylene glycol ester is mixed diesters of caprylic and capric acids. ",
          "dependencies": "16"
        },
        {
          "claim_number": 20,
          "claim_text": "The process according to claim 1 or 2 wherein, the organic solvent is selected from the group comprising ethers, hydrocarbons, esters, and combinations thereof. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 21,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is hydrophilic and is incorporated into the first aqueous component. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 22,
          "claim_text": "The process according to claim 1 or 2 wherein, the emulsification of the two immiscible components is carried out using a method selected from the group consisting of mechanical agitation, ultrasonic energy, and nozzle atomization. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 23,
          "claim_text": "The process according to claim 1 or 2 wherein, the formation of the solvent spherules is carried out using methods selected from the group consisting of mechanical agitation, ultrasonic energy, nozzle atomization, and combinations thereof. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 24,
          "claim_text": "The process according to claim 1 or 2 wherein, the removing of the organic solvent is by a method selected from the group consisting of sparging, rotary evaporation, passing gas over the solvent spherules, and combinations thereof. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 25,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is cytarabine. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 26,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is morphine. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 27,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is hydromorphone. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 28,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is leuprolide. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 29,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is a nucleic acid. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 30,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is interleukin-2. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 31,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is amikacin. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 32,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is granulocyte colony stimulating factor. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 33,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is insulin. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 34,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is hepatitis B vaccine. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 35,
          "claim_text": "The process of claim 23 wherein, the protein is an antibody or a vaccine. ",
          "dependencies": "23"
        },
        {
          "claim_number": 36,
          "claim_text": "The process of claim 23 wherein, the antiparasitic is an antiviral or an antifungal. ",
          "dependencies": "23"
        },
        {
          "claim_number": 37,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is .alpha.-interferon. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 38,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is methotrexate. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 39,
          "claim_text": "The process according to claim 1 or 2 wherein, the biologically active substance is granulocyte-macrophage colony stimulating factor. ",
          "dependencies": "1,2"
        },
        {
          "claim_number": 40,
          "claim_text": "The process according to claim 1 or 2 wherein, the lipid component further comprises plant sterols. ",
          "dependencies": "1,2"
        }
      ]
    },
    {
      "patent_number": "6241999",
      "expiration_date": "2016-09-01",
      "published_date": "2006-09-01",
      "application_numbers": [
        "NDA021671"
      ],
      "claims": [
        {
          "claim_number": 1,
          "claim_text": "1. A method for increasing the percent of at least one compound encapsulated in a liposome made from a given formulation comprising:(a) forming a liposome, by any conventional means, containing at least one encapsulated compound and having at least one first amphipathic lipid having a carbon chain from about 1 to about 12 carbons in the lipid component of the formulation;(b) determining the percent amount of encapsulated compound;(c) substituting said at least one first amphipathic lipid having a carbon chain from about 1 to about 12 carbons in the lipid component of the formulation with at least one second amphipathic lipid with a substantially similar chemical structure, having from 1 to 16 more carbons in a fatty acyl chain of the second lipid;wherein the increased number of carbons in the fatty acyl chain of the second lipid results in an increase in the percent of said at least one compound encapsulated in the formulation.",
          "dependencies": null
        },
        {
          "claim_number": 2,
          "claim_text": "2. The method of claim 1 wherein the percent of the compound encapsulated is increased to a value between about 7.5 and 50 percent.",
          "dependencies": "1"
        },
        {
          "claim_number": 3,
          "claim_text": "3. The method of claim 1 wherein the number of carbons is increased from 12 or less to a number in the range from 13 to about 22.",
          "dependencies": "1"
        },
        {
          "claim_number": 4,
          "claim_text": "4. The method of claim 3 wherein the amphipathic lipid is a phospholipid.",
          "dependencies": "3"
        },
        {
          "claim_number": 5,
          "claim_text": "5. The method of claim 3 wherein the amphipathic lipid is a saturated phospholipid.",
          "dependencies": "3"
        },
        {
          "claim_number": 6,
          "claim_text": "6. The method of claim 3 wherein the percent of the compound encapsulated is increased to a value between about 30 and 85 percent.",
          "dependencies": "3"
        },
        {
          "claim_number": 7,
          "claim_text": "7. The method of claim 4 wherein the phospholipid is selected from the group consisting of1,2-dioleoyl-sn-glycero-3-phosphocholine,1,2-dilauroyl-sn-glycero-3-phosphocholine,1,2-dimyristoyl-sn-glycero-3-phosphocholine,1,2-dipalmitoyl-sn-glycero-3-phosphocholine,1,2-distearoyl-sn-glycero-3-phosphocholine,1,2-diarachidoyl-sn-glycero-phosphocholine,1,2-dibehenoyl-sn-glycero-3-phosphocholine,1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine,1,2-dieicosenoyl-sn-glycero-3-phosphocholine,1,2-dierucoyl-sn-glycero-3-phosphocholine,1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol and1,2-dioleoyl-sn-glycero-3-phosphoglycerol.",
          "dependencies": "4"
        },
        {
          "claim_number": 8,
          "claim_text": "8. The method of claim 1 wherein the fatty acyl chain in the first amphipathic lipid contains 14 carbons and the increase is by a minimum of 2 carbons.",
          "dependencies": "1"
        },
        {
          "claim_number": 9,
          "claim_text": "9. The method of claim 1 wherein the fatty acyl chain in the first lipid contains 16 carbons and the increase is by a minimum of 2 carbons.",
          "dependencies": "1"
        },
        {
          "claim_number": 10,
          "claim_text": "10. The method of claim 1 wherein the fatty acyl chain in the first lipid contains 18 carbons and the increase is by 2 carbons.",
          "dependencies": "1"
        },
        {
          "claim_number": 11,
          "claim_text": "11. The method of claim 1 or 4 wherein the increase is by 4 carbons.",
          "dependencies": "1,4"
        },
        {
          "claim_number": 12,
          "claim_text": "12. The method of claim 1 or 4 wherein the increase is by 6 carbons or more.",
          "dependencies": "1,4"
        },
        {
          "claim_number": 13,
          "claim_text": "13. The method of claim 4 wherein the acyl chain is an SN.sub.1 or an SN.sub.2 chain, or both.",
          "dependencies": "4"
        },
        {
          "claim_number": 14,
          "claim_text": "14. The method of claim 13 wherein the increase is in the SN.sub.1 chain.",
          "dependencies": "13"
        },
        {
          "claim_number": 15,
          "claim_text": "15. The method of claim 13 wherein the increase is in the SN.sub.2 chain.",
          "dependencies": "13"
        },
        {
          "claim_number": 16,
          "claim_text": "16. The method of claim 13 wherein the increase is in both the SN.sub.1 chain and the SN.sub.2 chain.",
          "dependencies": "13"
        },
        {
          "claim_number": 17,
          "claim_text": "17. The method of claim 1 wherein steps (a) and (b) are performed only until the desired encapsulation efficiency is determined.",
          "dependencies": "1"
        },
        {
          "claim_number": 18,
          "claim_text": "18. The method of claim 1 wherein only step (c) is performed once the desired formulation has been determined.",
          "dependencies": "1"
        },
        {
          "claim_number": 19,
          "claim_text": "19. The method of claim 1 wherein 2 or more first amphipathic lipids having a carbon chain from about 1 to about 12 carbons in the lipid component of the formulation are substituted with second amphipathic lipids with substantially similar chemical structures, but having from 1 to 16 more carbons in the fatty acyl chains of the second lipid.",
          "dependencies": "1"
        },
        {
          "claim_number": 20,
          "claim_text": "20. The method of claim 1 wherein 2 or more compounds are encapsulated.",
          "dependencies": "1"
        }
      ]
    }
  ]
}
